Quite a short question for quite a complex issue!

NF-kappaB englobes a wide family of transcription factors which is found in every cell in every place in the organism, and beyond that, regulating a surprisingly high number of actions (even contradictory, a good open window for microRNA and epigenetics) that makes selectiveness in therapeutic approach an even more complex aim. In grosso modo, what should you have in mind when coming up with this TF and its activation? Look it up according to its functions and what may trigger them:

- IMMUNE SYSTEM: Activators such as IL-1, TNF alpha, TLR, ROS or LPS.

- INFLAMMATION AND STRESS

- BONE REMODELLING: Important role of RANK ligands and osteoprotegerin (and great interest for new biologicals in terms of osteoporosis such as denosumab)

- APOPTOSIS and PROLIFERATION: This is a wide more complex topic and maybe the most researched for its involvement in cancer.

I strongly reccommend you to read some reviews of its regulation, such as http://www.ncbi.nlm.nih.gov/pubmed/16626297

I'm sorry to respond so lately .

Thank u,But my question may be not very clear.

Actually, I want to know if it is meaningful to investigate some synthetic small molecular activators for NF-KappaB

.

They are activators of the transcription-regulating factor "nuclear factor 'kappa-light-chain-enhancer' of activated B-cells". Inhibition leads to reduced expression of down-stream targets (e.g. genes involved in inflammatory response (cytokines), blood coagulation (Tissue Factor), cell attachment etc.) and consequently reduced activity in these functional fields.